Mymetics Corp (MYMX)

[bow-tie]

Mambisa's results are evaluated in its short vaccination schedule
CUBANEW/ACN
02 FEBRUARY 2021

Ayala Avila explained that the intramuscular and intranasal route of administration is explored, one group is evaluated with a first intramuscular immunization and two others by nasal route (with spray); while another group only studies the nasal route with the three immunizations.

Mambisa (CIGB-669) is based on the formulation of the RBD (Receptor Binding Domain) protein and an immunopotentiator evaluated by the center: the Hepatitis B nucleocapsid antigen.

In turn, Abdala, which began its Phase II study on Monday, is based on the formulation of the recombinant RBD protein adjuvant in aluminum hydroxide.

Both candidates began their studies on December 7, 2020 and 56 days after administration are safe, with mild adverse events.

The RBD recombinant protein is produced by the CIGB in yeast cells, a technology widely used in Cuba and the world to obtain subunit vaccines.


http://www.cubanews.acn.cu/cuba/12361-mambisa-s-results-are-evaluated-in-its-short-vaccination-schedule


HAVANA, Cuba, Feb 5 (ACN) The Center for Genetic Engineering and Biotechnology (CIGB) expects to advance in March to Phase III of the clinical trials of the Abdala vaccine candidate (CIGB-66), after more than 300 individuals participated in the second stage of its short vaccination scheme.
http://www.cubanews.acn.cu/science/12417-cuba-abdala-and-mambisa-vaccines-clinical-trials-progress-with-encouraging-results

Cuba announces Phase 3 for vaccines Abdala (CIGB-66) and ...
www.emergency-live.com/health-and-safety/cuba...
Cuba, the Caribbean island's independently produced vaccines are now in their final definition phase. Abdala (CIGB-66) and Soberana 02...
https://www.emergency-live.com/health-and-safety/cuba-ministry-of-health-announces-phase-3-for-abdala-cigb-66-and-soberana-02-its-two-covid-19-vaccines/